1Gregory CR, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechnical injiury: its effect on celllar, gowth factor and cytokine responses in injured vessels. Transplantation, 1993,55:1409-1418.
2Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after ballon angioplasty in porcin coronary arteries by targeting regulators of the cell cycle. Circulation, 1999, 99: 2164-2170.
3Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation,2001,104:1188-1193.
4Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res, 1995,76:412-417.
5Pooh M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest, 1996,98:2277-2283.
6Luo Y, Marx SO, Kiyokawa H, et al. Rapamycin resistance tied to defective regulation of p27^kipl. Mol Cell Biol, 1996,16:6744-6751.
7Sun J, Marx SO, Chea H-J, et al. A role for p27^kipl in vascular smooth muscle cellmigration. Citoalation, 2001,103:2967-2972.
8Braun-Dullaeus RC, Mann MJ, Dzau VJ,et al. Cell cycle progression:new therapeutic target for vascular proliferative disease. Circulation,1998,98:82-89.
9Roque M, Reis ED, Cordon-Cardo C, et al. Effect of p27 deficiency and rapanmcin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mous model, Lab Invest, 2001,81:895-903.
10Sousa JE, Costa MA, Abizaid AC, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and threedimensional intravascular ultrasound study. Circulation, 2001, 103:192-195.
4Gregory BM,Huiep,Billingham ME,et al.Rapamycin inhibits arterial intimal thickening caused by both allominmune and mechanical injury:Its effect on cellular,growth factor,and cytokine reponse in injured vessels[J].Transplantation,1993,55:1409-1418.
5Willerson JT.Systemic and local inflammation in patients with unstable atherosclerotic plaques[J].Prog Cardiovasc Dis,2002,44(6):469-478.
6Zee RY,Hegener HH,Fernandez-Cruz A,et al.C-reactive protein gene polymorphisms and the incidence of post-angioplasty restenosis[J].Atherosclerosis,2004,176(2):393-396.
7Albert CM,Ma J,Rifai N,et al.Prospective study of C-reactive protein,homocysteine,and plasma lipid levels as predictors of sudden cardiac death[J].Circulation,2002,105(22):2595-2599.
8Koenig W,Lowel H,Baumert J,et al.C-reactive protein modulates risk prediction based on the Framingham Score:implications for future risk assessment:results from a large cohort study in southern Germany[J].Circulation,2004,109(11):1349-1353.
9Serruys PW, Degertekin M, Tanabe K, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound "analysis from the TAXUS 11 trial. Circulation,2004,109 : 627-633.
10Grube E, Silber S, HaupUnann KE, el al. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation, 2003,107 : 38-42.
